Fig. 4.

Evobrutinib inhibits B-cell APC function. Oral treatment of C57/BL6 mice with control or 1, 3 or 10 mg/kg evobrutinib started 7 days prior to immunization with 75 µg conformational MOG1-117 protein. a Splenic B cells were isolated from mice 12 days after immunization; T cells were obtained from unimmunized, untreated 2D2 mice. T cells were co-cultured with B cells for 72 h in the presence of the indicated concentrations MOG protein. Evobrutinib concentrations equivalent to serum levels 1 h after oral dosing were added every 24 h. b T cell proliferation was analyzed by CFSE dilution. T cell differentiation was analyzed by intracellular flow cytometry for the production of c) IFN-γ, d IL-17 and e FoxP3. Mean ± SEM or median, n = 4. Representative data from at least 2 independent experiments, *p < 0.05,***p < 0.001, ****p < 0.0001